TY - JOUR
T1 - Comparison between chemoradiotherapy and bioradiotherapy after induction chemotherapy in head and neck cancer
AU - Suzuki, Chiaki
AU - Hayashi, Tomomasa
AU - Kitamura, Morimasa
AU - Tateya, Ichiro
AU - Kishimoto, Yo
AU - Ishikawa, Seiji
AU - Inokuchi, Haruo
AU - Yoshimura, Michio
AU - Nomura, Motoo
AU - Hirano, Shigeru
N1 - Publisher Copyright:
© 2016, Japanese Journal of Head and Neck Cancer. All rights reserved.
PY - 2016
Y1 - 2016
N2 - Objective: The aim of this study was to evaluate the completion rate and the toxicity of chemoradiotherapy with CDDP (CDDP-RT)and bioradiotherapy with cetuximab (BRT) following induction chemotherapy (ICT) in locally advanced head and neck squamous cell carcinoma (LA-SCCHN). Materials and Methods: This retrospective study includes 22 patients with ICT followed by CDDP-RT and 18 patients with cetuximab-RT at our hospital from April 2009 to December 2014. We compared CDDP-RT and cetuximab-RT in terms of the ratio of adverse events (CTCAE ver. 4), nutrition support, and treatment compliance. Results: Treatment compliance was better in cetuximab-RT than CDDP-RT. The adverse events of neutro-penia, anemia and creatinine increase were almost equal between CDDP-RT and cetuximab-RT. Acute mucosi-tis, dermatitis and dysphagia were more frequent in cetuximab-RT. Dysphagia tended to be more prolonged in cetuximab-RT than CDDP-RT. Conclusion: In terms of compliance, cetuximab-RT seems to be more suitable after induction chemotherapy. However, cetuximab-RT causes more severe mucositis and dysphagia, which warrants good support.
AB - Objective: The aim of this study was to evaluate the completion rate and the toxicity of chemoradiotherapy with CDDP (CDDP-RT)and bioradiotherapy with cetuximab (BRT) following induction chemotherapy (ICT) in locally advanced head and neck squamous cell carcinoma (LA-SCCHN). Materials and Methods: This retrospective study includes 22 patients with ICT followed by CDDP-RT and 18 patients with cetuximab-RT at our hospital from April 2009 to December 2014. We compared CDDP-RT and cetuximab-RT in terms of the ratio of adverse events (CTCAE ver. 4), nutrition support, and treatment compliance. Results: Treatment compliance was better in cetuximab-RT than CDDP-RT. The adverse events of neutro-penia, anemia and creatinine increase were almost equal between CDDP-RT and cetuximab-RT. Acute mucosi-tis, dermatitis and dysphagia were more frequent in cetuximab-RT. Dysphagia tended to be more prolonged in cetuximab-RT than CDDP-RT. Conclusion: In terms of compliance, cetuximab-RT seems to be more suitable after induction chemotherapy. However, cetuximab-RT causes more severe mucositis and dysphagia, which warrants good support.
UR - http://www.scopus.com/inward/record.url?scp=84969981480&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969981480&partnerID=8YFLogxK
U2 - 10.5981/jjhnc.42.87
DO - 10.5981/jjhnc.42.87
M3 - Article
AN - SCOPUS:84969981480
SN - 1349-5747
VL - 42
SP - 87
EP - 91
JO - Japanese Journal of Head and Neck Cancer
JF - Japanese Journal of Head and Neck Cancer
IS - 1
ER -
